SCHEMBL4508089

SCHEMBL4508089

O=C(O)C1CNCC(NS(=O)(=O)c2ccccc2)C1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
REN P00797 6/20 0.59
TSHR P16473 1/20 0.49
ALDH1A1 P00352 1/20 0.49
DPP4 P27487 1/20 0.47
SLC6A11 P48066 1/20 0.44
MMP1 P03956 3/20 0.41
MMP2 P08253 3/20 0.41
MMP3 P08254 3/20 0.41
MMP9 P14780 3/20 0.41
MMP7 P09237 1/20 0.41
CTSB P07858 3/20 0.41
CTSK P43235 3/20 0.41
UCHL1 P09936 2/20 0.41
CTSS P25774 2/20 0.41
CTSC P53634 2/20 0.41
USP30 Q70CQ3 2/20 0.41
CTSL P07711 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4508093 1.00 REN (0.59) RENTSHRALDH1A1DPP4SLC6A11
SCHEMBL4502147 0.92 REN (0.57) RENTSHRALDH1A1SLC6A11MMP1
SCHEMBL4502144 0.92 REN (0.57) RENTSHRALDH1A1SLC6A11MMP1
SCHEMBL4499196 0.88 MMP2 (0.58) RENTSHRALDH1A1MMP1MMP2
SCHEMBL4499198 0.88 MMP2 (0.58) RENTSHRALDH1A1MMP1MMP2
SCHEMBL4493886 0.87 REN (0.56) RENTSHRALDH1A1DPP4MMP2
SCHEMBL4514576 0.87 REN (0.53) RENTSHRALDH1A1SLC6A11MMP1
SCHEMBL4493885 0.87 REN (0.56) RENTSHRALDH1A1DPP4MMP2
SCHEMBL4494687 0.87 REN (0.68) RENTSHRALDH1A1
SCHEMBL4514580 0.87 REN (0.53) RENTSHRALDH1A1SLC6A11MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP disclosed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 REN 1/4885TSHR 933/4885ALDH1A1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.